Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Acquisitions & Divestments (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Change in Acquisitions & Divestments for 10 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments fell 70.87% year-over-year to $7.1 million, compared with a TTM value of $67.0 million through Dec 2025, down 45.73%, and an annual FY2025 reading of $67.0 million, down 45.73% over the prior year.
  • Change in Acquisitions & Divestments was $7.1 million for Q4 2025 at Heron Therapeutics, down from $18.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $58.0 million in Q2 2021 and bottomed at $7.1 million in Q4 2025.
  • Average Change in Acquisitions & Divestments over 5 years is $30.3 million, with a median of $28.9 million recorded in 2023.
  • The sharpest move saw Change in Acquisitions & Divestments plummeted 86.17% in 2021, then surged 122.56% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $14.0 million in 2021, then soared by 50.0% to $21.0 million in 2022, then dropped by 29.76% to $14.8 million in 2023, then skyrocketed by 65.23% to $24.4 million in 2024, then tumbled by 70.87% to $7.1 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for HRTX at $7.1 million in Q4 2025, $18.0 million in Q3 2025, and $16.7 million in Q2 2025.